A Randomized, Open-label Phase II Efficacy and Safety Study of Atezolizumab in Combination With FLOT Versus FLOT Alone in Patients With Gastric Cancer and Adenocarcinoma of the Oesophago-gastric Junction (MO30039) - The DANTE Trial
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2019
At a glance
- Drugs Atezolizumab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms The DANTE Trial
- 17 Sep 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 28 Jun 2018 Planned initiation date changed from 1 Feb 2018 to 1 Jul 2018.